Evidence map›Paper›PMID 29751775›Full record

ArticleStem cell research & therapy2018

cxcl12-engineered endothelial progenitor cells enhance neurogenesis and angiogenesis after ischemic brain injury in mice.

Yaning Li, Shuang Chang, Wanlu Li, Guanghui Tang, Yuanyuan Ma, Yanqun Liu, Fang Yuan, Zhijun Zhang, Guo-Yuan Yang, Yongting Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 95 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Angiogenesis after ischemic stroke.Acta pharmacologica Sinica · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yaning LiSchool of Biomedical Engineering and Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, 1954 Hua Shan Road, Shanghai, 200030, China.
Shuang ChangSchool of Biomedical Engineering and Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, 1954 Hua Shan Road, Shanghai, 200030, China.
Wanlu LiSchool of Biomedical Engineering and Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, 1954 Hua Shan Road, Shanghai, 200030, China.
Guanghui TangSchool of Biomedical Engineering and Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, 1954 Hua Shan Road, Shanghai, 200030, China.
Yuanyuan MaDepartment of Neurology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China.
Yanqun LiuDepartment of Neurology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China.
Fang YuanSchool of Biomedical Engineering and Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, 1954 Hua Shan Road, Shanghai, 200030, China.
Zhijun ZhangSchool of Biomedical Engineering and Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, 1954 Hua Shan Road, Shanghai, 200030, China.
Guo-Yuan YangSchool of Biomedical Engineering and Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, 1954 Hua Shan Road, Shanghai, 200030, China. gyyang0626@163.com.
Yongting WangSchool of Biomedical Engineering and Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, 1954 Hua Shan Road, Shanghai, 200030, China. ytwang@sjtu.edu.cn.ORCID 0000-0002-5841-6557
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIschemic stroke causes a multitude of brain damage. Neurovascular injury and myelin sheath degradation are two manifestations of ischemic brain damage. Therapeutic strategies aiming only at repairing the neural components or the vessels cannot efficiently restore neurological function. Endothelial progenitor cells (EPCs) have the advantages of both promoting angiogenesis and secreting trophic factors that would promote neurogenesis. Chemokine cxcl12 gene therapy has also been shown to promote angiogenesis, neurogenesis, and remyelination, attracting EPCs, neural progenitor cells, and oligodendrocyte progenitor cells (OPCs) to the injured sites of the brain. In this work, we tested whether these two therapeutics can be combined by genetically engineering the EPCs with cxcl12 to harness the synergistic effects of these two interventions.

methodsWe used lentivirus (LV) to deliver cxcl12 gene into human umbilical cord blood EPCs to generate the engineered CXCL12-EPCs, which were then delivered into the perifocal region at 1 week after permanent middle cerebral artery occlusion to investigate the effects of CXCL12-EPCs on the functional recovery and angiogenesis, neurogenesis, and remyelination in ischemic stroke mice. Green fluorescent protein (gfp) gene-modified EPCs and LV-CXCL12 gene therapy were used as controls.

resultsCXCL12-EPC treatment significantly reduced brain atrophy and improved neurobehavioral function at 5 weeks after brain ischemia. The treatment resulted in increased blood vessel density and myelin sheath integrity, and promoted neurogenesis, angiogenesis, and the proliferation and migration of OPCs. In-vitro data showed that CXCL12-EPCs performed better in proliferation and tube formation assays and expressed a higher level of vascular endothelial growth factor compared to GFP-EPCs.

conclusionsThe synergistic treatment of CXCL12-EPCs outperformed the single therapies of GFP-EPCs or LV-CXCL12 gene therapy in various aspects related to post-ischemic brain repair. cxcl12-engineered EPCs hold great potential in the treatment of ischemic stroke.

Indexed as

AnimalsBrain InjuriesBrain IschemiaChemokine CXCL12Endothelial Progenitor CellsGenetic TherapyHumansMaleMiceNeovascularization, PathologicNeurogenesisChemokine CXCL12CXCL12 protein, human

Identifiers

PMID29751775
PMCPMC5948880
OpenAlexW2799399950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.